Dallas, TX -- (SBWIRE) -- 06/10/2015 -- The report "Friedreich Ataxia – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Friedreich Ataxia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Friedreich Ataxia and special features on late-stage and discontinued projects.

Complete report on Friedreich Ataxia with 29 market data tables and 14 figures, spread across 85 pages is available at http://www.rnrmarketresearch.com/friedreich-ataxia-pipeline-review-h1-2015-market-report.html

Companies discussed in this Friedreich Ataxia – Pipeline Review, H1 2015 report include AAVLife, Bioblast Pharma Ltd., BioMarin Pharmaceutical Inc., Biovista Inc., Catabasis Pharmaceuticals, Inc., Edison Pharmaceuticals, Inc., Horizon Pharma plc, MI.TO. Technology S.r.L., Reata Pharmaceuticals, Inc., Shire Plc, STATegics, Inc., Varinel, Inc.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are BB-FA, BVA-202, BVA-203, CAT-4001, Cell Therapy for Friedreich's Ataxia, diazoxide, Gene Therapy for Friedreich's ataxia, Gene Therapy for Friedreich's Ataxia, Gene Therapy to Activate Frataxin for Friedreich's Ataxia, Gene Therapy to Activate Frataxin for Friedrich's Ataxia, interferon gamma-1b (recombinant), Oligonucleotide to Activate Frataxin for Friedreich's Ataxia, RG-2833, RG-3250, RTA-408, SHP-622, STSE-15, VAR-10100, VAR-10300, vatiquinone, VYFXNO-1.

Order a purchase copy of this report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=390982
(This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases Cover by this report includes:

-Apr 10, 2015: Horizon Pharma Receives FDA Fast Track Designation for ACTIMMUNE in the Treatment of Friedreich's Ataxia

-Mar 26, 2015: BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia

-Mar 24, 2015: Catabasis Pharmaceuticals to Present at International Ataxia Research Conference

-Feb 13, 2015: Horizon Pharma Submits Investigational New Drug Application for ACTIMMUNE in the Treatment of Friedreich's Ataxia

-Jan 29, 2015: Reata Enrolls First Patient in the MOXIe Study, a Phase 2/3 Study Examining RTA 408 in Friedreich's Ataxia Patients

-Dec 17, 2014: BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia

-Oct 09, 2014: Horizon Pharma Announces Presentation of ACTIMMUNE Phase 2 Data in Friedreich's Ataxia

-Oct 03, 2014: Horizon Pharma Receives Orphan-Drug Designation for ACTIMMUNE (Interferon gamma-1b) in Friedreich's Ataxia

-Sep 30, 2014: Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies

-Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia

Inquire for Disocunt @ http://www.rnrmarketresearch.com/contacts/discount?rname=390982
(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Friedreich Ataxia, H1 2015 10
Number of Products under Development for Friedreich Ataxia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Products under Development by Companies, H1 2015 16
Products under Development by Companies, H1 2015 (Contd..1) 17
Products under Investigation by Universities/Institutes, H1 2015 18
Friedreich Ataxia - Pipeline by AAVLife, H1 2015 19
Friedreich Ataxia - Pipeline by Bioblast Pharma Ltd., H1 2015 20
Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 21
Friedreich Ataxia - Pipeline by Biovista Inc., H1 2015 22
Friedreich Ataxia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 23
Friedreich Ataxia - Pipeline by Edison Pharmaceuticals, Inc., H1 2015 24
Friedreich Ataxia - Pipeline by Horizon Pharma plc, H1 2015 25
Friedreich Ataxia - Pipeline by MI.TO. Technology S.r.L., H1 2015 26
Friedreich Ataxia - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 27
Friedreich Ataxia - Pipeline by Shire Plc, H1 2015 28
Friedreich Ataxia - Pipeline by STATegics, Inc., H1 2015 29
Friedreich Ataxia - Pipeline by Varinel, Inc., H1 2015 30
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Friedreich Ataxia Therapeutics - Recent Pipeline Updates, H1 2015 68
Friedreich Ataxia - Dormant Projects, H1 2015 76
Friedreich Ataxia - Discontinued Products, H1 2015 77

List of Figures
Number of Products under Development for Friedreich Ataxia, H1 2015 10
Number of Products under Development for Friedreich Ataxia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Products, H1 2015 15
Assessment by Monotherapy Products, H1 2015 31
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 33
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Explore more reports on Central Nervous System (CNS) therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics